The present invention relates to compositions comprising a P-gp inducer, for topical use in preventing one or more side effects of chemotherapeutics, which chemotherapeutics are transported out of cells by P-gp. Especially chemotherapy-induced peripheral neuropathy (CIPN) is a relevant side effect to treat/avoid, since CIPN may be a dose limiting side effect of chemotherapy. The invention also relates to kits and to cancer treatment of a subgroup of patients, which subgroup has been topically pretreated with a P-gp inducer.

The present invention relates to compositions comprising a P-gp inducer, for topical use in preventing one or more side effects of chemotherapeutics, which chemotherapeutics are transported out of cells by P-gp. Especially chemotherapy-induced peripheral neuropathy (CIPN) is a relevant side effect to treat/avoid, since CIPN may be a dose limiting side effect of chemotherapy. The invention also relates to kits and to cancer treatment of a subgroup of patients, which subgroup has been topically pretreated with a P-gp inducer.

The present invention relates to compositions comprising a P-gp inducer, for topical use in preventing one or more side effects of chemotherapeutics, which chemotherapeutics are transported out of cells by P-gp. Especially chemotherapy-induced peripheral neuropathy (CIPN) is a relevant side effect to treat/avoid, since CIPN may be a dose limiting side effect of chemotherapy. The invention also relates to kits and to cancer treatment of a subgroup of patients, which subgroup has been topically pretreated with a P-gp inducer.

The present invention relates generally to hybrid polymer (e.g., polyphosphazene) based drug delivery platforms and to methods of producing, evaluating, administering, and treating subjects with the same. More particularly, the present invention provides polyphosphazene based drug delivery platforms comprising one or more polyphosphazenes with controlled molecular weights and/or polydispersities as well as selective methods for associating one or more therapeutic dmg (or prodrug) substances to the polyphos-phazenes.

The present invention relates generally to hybrid polymer (e.g., polyphosphazene) based drug delivery platforms and to methods of producing, evaluating, administering, and treating subjects with the same. More particularly, the present invention provides polyphosphazene based drug delivery platforms comprising one or more polyphosphazenes with controlled molecular weights and/or polydispersities as well as selective methods for associating one or more therapeutic dmg (or prodrug) substances to the polyphos-phazenes.

Provided are methods of using an anti-cancer agent's cell cycle-related, cell-killing activity to identify it as an effective combination with YM155 monobromide for treating MYC-associated cancers, and related kits, compositions, methods of screening, and methods for treating cancer in a subject in need thereof.

Provided are methods of using an anti-cancer agent's cell cycle-related, cell-killing activity to identify it as an effective combination with YM155 monobromide for treating MYC-associated cancers, and related kits, compositions, methods of screening, and methods for treating cancer in a subject in need thereof.

The present invention addresses the problem of providing a dissolving agent which improves the solubility of a compound such as curcumin that contains an aromatic ring without changing the structure of this compound. The present invention is a compound which is represented by general formula (1). (In the formula, R.sup.1 is an alkyl group having 7 to 24 carbon atoms or an alkenyl group; A.sup.1 represents an optionally substituted aryl group; Z.sup.1 represents a single bond, an alkylene group having from 1 to 6 carbon atoms, or an alkenylene group having from 2 to 5 carbon atoms; and Z.sup.2 represents a divalent linking group.)

##STR00001##

The present disclosure relates generally to methods of treating (i) a tumor (e.g., a solid tumor, an advanced solid tumor, a cancer), (ii) tumor-related weight loss, or (iii) tumor-related cachexia in a human patient, the method comprising administering to the human patient an anti-GDNF family receptor alpha-like (GFRAL) antibody, wherein the antibody inhibits GFRAL binding to Ret proto-oncogene (RET). The present disclosure also relates generally to methods of treating pancreatic cancer (e.g., an advanced pancreatic cancer, a metastatic pancreatic cancer, a pancreatic adenocarcinoma, a metastatic pancreatic adenocarcinoma, an MSI-H pancreatic cancer, a pancreatic ductal adenocarcinoma, a metastatic pancreatic ductal adenocarcinoma) in a human patient, comprising administering to the human patient (i) an anti-GFRAL antibody, wherein the antibody inhibits GFRAL binding to RET; (ii) paclitaxel; and (iii) gemcitabine.

The present disclosure relates generally to methods of treating (i) a tumor (e.g., a solid tumor, an advanced solid tumor, a cancer), (ii) tumor-related weight loss, or (iii) tumor-related cachexia in a human patient, the method comprising administering to the human patient an anti-GDNF family receptor alpha-like (GFRAL) antibody, wherein the antibody inhibits GFRAL binding to Ret proto-oncogene (RET). The present disclosure also relates generally to methods of treating pancreatic cancer (e.g., an advanced pancreatic cancer, a metastatic pancreatic cancer, a pancreatic adenocarcinoma, a metastatic pancreatic adenocarcinoma, an MSI-H pancreatic cancer, a pancreatic ductal adenocarcinoma, a metastatic pancreatic ductal adenocarcinoma) in a human patient, comprising administering to the human patient (i) an anti-GFRAL antibody, wherein the antibody inhibits GFRAL binding to RET; (ii) paclitaxel; and (iii) gemcitabine.